Senores Pharmaceuticals · NSE: SENORES · BSE: 544319
Q4 FY25 results · Jan–Mar 2025
Senores Pharmaceuticals reported revenue from operations of ₹114.21 crore and net profit of ₹17.97 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 114.21 | — | — | 103.02 | +10.9% |
| Other income | 11.77 | — | — | 5.16 | +128.3% |
| Total income | 125.98 | — | — | 108.17 | +16.5% |
| Profit before tax | 20.68 | — | — | 20.48 | +1.0% |
| Net profit for the period | 17.97 | — | — | 16.43 | +9.4% |
| EPS, basic (₹) | 3.81 | — | — | 5.04 | −24.4% |
| Net margin (%) | 15.7 | — | 15.9 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 11.86 | — | — | 9.59 | +23.7% |
| Other income | 9.25 | — | — | 7.19 | +28.7% |
| Total income | 21.11 | — | — | 16.78 | +25.8% |
| Profit before tax | 2.90 | — | — | 1.32 | +119.5% |
| Net profit for the period | 2.02 | — | — | 1.07 | +87.9% |
| EPS, basic (₹) | 0.39 | — | — | 0.32 | +23.0% |
| Net margin (%) | 17.0 | — | 11.2 |
Consolidated
- Filed with BSE
- 15 May 2025, 19:24 IST
- Board meeting
- 15 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 May 2025, 19:24 IST
- Board meeting
- 15 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE